WO2019066442A3 - 제2형 당뇨병 치료를 위한 락토페린 기반의 유전자 전달체 - Google Patents

제2형 당뇨병 치료를 위한 락토페린 기반의 유전자 전달체 Download PDF

Info

Publication number
WO2019066442A3
WO2019066442A3 PCT/KR2018/011336 KR2018011336W WO2019066442A3 WO 2019066442 A3 WO2019066442 A3 WO 2019066442A3 KR 2018011336 W KR2018011336 W KR 2018011336W WO 2019066442 A3 WO2019066442 A3 WO 2019066442A3
Authority
WO
WIPO (PCT)
Prior art keywords
lactoferrin
type
based gene
diabetes treatment
gene carrier
Prior art date
Application number
PCT/KR2018/011336
Other languages
English (en)
French (fr)
Other versions
WO2019066442A2 (ko
Inventor
이동윤
이창우
이승아
Original Assignee
한양대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020180107204A external-priority patent/KR102144380B1/ko
Application filed by 한양대학교 산학협력단 filed Critical 한양대학교 산학협력단
Priority to US16/651,195 priority Critical patent/US11471540B2/en
Publication of WO2019066442A2 publication Critical patent/WO2019066442A2/ko
Publication of WO2019066442A3 publication Critical patent/WO2019066442A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

본 발명은 생체적합성 고분자 백본 및 상기 생체적합성 고분자 백본에 공유결합으로 연결된 페길화된 락토페린(pegylated lactoferrin)을 포함하는 유전자 전달용 복합체에 관한 것으로, 상기 유전자 전달용 복합체는 개체 내에 경구로 투여되어 락토페린 수용체를 통하여 체내로 흡수될 수 있으며, 표적 유전자를 생체 내로 전달하여 발현시킬 수 있다.
PCT/KR2018/011336 2017-09-27 2018-09-21 제2형 당뇨병 치료를 위한 락토페린 기반의 유전자 전달체 WO2019066442A2 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/651,195 US11471540B2 (en) 2017-09-27 2018-09-21 Lactoferrin-based gene carrier for type 2 diabetes treatment

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20170124935 2017-09-27
KR10-2017-0124935 2017-09-27
KR10-2018-0107204 2018-09-07
KR1020180107204A KR102144380B1 (ko) 2017-09-27 2018-09-07 제2형 당뇨병 치료를 위한 락토페린 기반의 유전자 전달체

Publications (2)

Publication Number Publication Date
WO2019066442A2 WO2019066442A2 (ko) 2019-04-04
WO2019066442A3 true WO2019066442A3 (ko) 2019-08-08

Family

ID=65902567

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/011336 WO2019066442A2 (ko) 2017-09-27 2018-09-21 제2형 당뇨병 치료를 위한 락토페린 기반의 유전자 전달체

Country Status (1)

Country Link
WO (1) WO2019066442A2 (ko)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110009313A1 (en) * 2008-03-14 2011-01-13 Nrl Pharma, Inc. Polyethylene glycolated lactoferrin complex and method of producing the same
WO2016020217A1 (en) * 2014-08-07 2016-02-11 Nestec S.A. A delivery system

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110009313A1 (en) * 2008-03-14 2011-01-13 Nrl Pharma, Inc. Polyethylene glycolated lactoferrin complex and method of producing the same
WO2016020217A1 (en) * 2014-08-07 2016-02-11 Nestec S.A. A delivery system

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE Nucleotide 15 July 2006 (2006-07-15), "Homo sapiens fibroblast growth factor 21, mRNA (cDNA clone MGC:21502 IMAGE:3881069), complete cds", XP055628112, retrieved from NCBI Database accession no. BC018404.1 *
ONISHI, HIRAKU ET AL.: "Preparation of chitosan/alginate/calcium complex microparticles loaded with lactoferrin and their efficacy on carrageenan-induced edema in rats", DRUG DEV. IND. PHARM., vol. 36, no. 8, 2010, pages 879 - 884, XP055628082 *
SUGIYAMA, A. ET AL.: "PEGylated lactoferrin enhanced its hepatoprotective effects on acute liver injury induced by carbon tetrachloride in rats", FOOD CHEM. TOXICOL., vol. 47, no. 7, 2009, pages 1453 - 1458, XP026157634, doi:10.1016/j.fct.2009.03.030 *

Also Published As

Publication number Publication date
WO2019066442A2 (ko) 2019-04-04

Similar Documents

Publication Publication Date Title
NZ598348A (en) Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels
AU2018240515A1 (en) Nucleic acids encoding CRISPR-associated proteins and uses thereof
MX2012010114A (es) Formulaciones concentradas de proteina y usos de las mismas.
TN2017000439A1 (en) Glucose-responsive insulin delivery system using hyoxia-sensitive nanocomposites
MX343360B (es) Conjugados peptidicos de agonistas del receptor de glp-1 y gastrina y su uso.
JP2012041342A5 (ko)
MX2017004592A (es) Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos.
JO2932B1 (en) Lyspro insulin compounds linked to PEG
WO2015149944A3 (en) Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
EP3211001A3 (en) Superagonists and antagonists of interleukin-2
MY188825A (en) High-concentration monoclonal antibody formulations
EP3192526A3 (en) Exosomes for delivery of biotherapeutics
JP2016532690A5 (ko)
NZ593641A (en) Extended soluble ph20 polypeptides and uses thereof
WO2010053545A3 (en) Apj receptor compounds
NZ602471A (en) Antagonists of activin-actriia and uses for increasing red blood cell levels
EP3792280A3 (en) Anti-blys antibody
NZ601677A (en) Improved cancer therapy based on tumor associated antigens derived from cyclin d1
EP4233978A3 (en) Oral delivery of active drug substances
MX2012007806A (es) Composiciones farmaceuticas para administracion oral de peptidos de insulina.
NZ608502A (en) Polypeptides that bind to human complement component c5
MX2010006650A (es) Materiales y metodos para el tratamiento de proliferacion vascular ocular patologica.
MX353649B (es) Proteinas protozoarias variables de superficie (vsp) como vehiculos para la administracion de farmacos.
WO2014145524A3 (en) Compositions and methods for immune tolerance induction to factor viii replacement therapies in subjects with hemophilia a
GEP20156332B (en) Pyrazoles as crth2 antagonists

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18861543

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18861543

Country of ref document: EP

Kind code of ref document: A2